PanGen Biotech Inc. (KOSDAQ:222110)
5,360.00
+50.00 (0.94%)
At close: Jan 23, 2026
PanGen Biotech Revenue
PanGen Biotech had revenue of 4.01B KRW in the quarter ending September 30, 2025, a decrease of -12.67%. This brings the company's revenue in the last twelve months to 15.27B, up 11.30% year-over-year. In the year 2024, PanGen Biotech had annual revenue of 14.67B with 100.58% growth.
Revenue (ttm)
15.27B
Revenue Growth
+11.30%
P/S Ratio
4.93
Revenue / Employee
n/a
Employees
n/a
Market Cap
75.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.67B | 7.36B | 100.58% |
| Dec 31, 2023 | 7.32B | 814.47M | 12.53% |
| Dec 31, 2022 | 6.50B | -1.43B | -18.08% |
| Dec 31, 2021 | 7.94B | 1.74B | 28.18% |
| Dec 31, 2020 | 6.19B | 3.31B | 114.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cell Biotech | 50.65B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 21.87B |
| Ark Solutions | 21.50B |
| MOA Life Plus | 9.80B |
| HLB Pep | 4.89B |
| EyeGene | 4.10B |
| Quratis | 2.28B |